Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 2c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.45), $0.02 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $480 thousand versus the consensus estimate of $1.44 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Sharon AI surges premarket; New Oriental gains, Medline slips